Medipharm Labs Corp T.LABS

Global cannabis pharmaceutical outlook

[alleyesonme]

https://www.precedenceresearch.com/cannabis-pharmaceuticals-market/amp

[Solid1]

 Insys Therapeutics, Inc. is bankrupt... people pay money for that ?

[Olaf123]

Restrains: Thus, while quality control and standardization are essential for ensuring patient safety and product efficacy in the cannabis pharmaceuticals market, excessive regulatory burden and uniformity requirements may hamper market growth by increasing costs and limiting product diversity and innovation. They include a struggling company like Avicanna. They don't include Medipharm which

[subaru1i]

Those reports can be very expensive and the only way those growth numbers gain credibility is if the projections are sourced from global pharmaceutical companies that intended to commercialize cannabis based pharmaceuticals.  And having written that within this forum, I can only say, we are in a very, very, sweet spot with LABS stock.   Nicely done alleyesonme and let the trend be

[Olaf123]

With Labs NDA, I'm not certain their research is very precise. October 2023. They had plenty of time.

[subaru1i]

I think the FDA would disagree with your comment of their research not being precise because the NIH is using product from LABS for clinical trials and the FDA also approved their facility.   I disagree with your comments w.r.t. NDA submission because that submission was executed in conjunction with their yet to be named global pharmaceutical partner and proof of that is that no record

[Olaf123]

Apotex ain't mentioned here either.

[mdjbrown]

Speaking of Apotex -  New Jersey lawsuit 2:23-cv23141 with Jazz / GW regarding Epidiolex moving right along https://www.pacermonitor.com/public/case/51713587/JAZZ_PHARMACEUTICALS_RESEARCH_UK_LIMITED_fka_GW_RESEARCH_LIMITED_v_APOTEX_INC_et_al 2:23-cv-23141